[ELGX] Endologix, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 7.19 Change: 0.12 (1.63%)
Ext. hours: Change: 0 (0%)

chart ELGX

Refresh chart

Strongest Trends Summary For ELGX

ELGX is in the medium-term down -58% below S&P in 1 year. In the long-term down -87% below S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States, Europe, and rest of the world. It provides minimally-invasive endovascular repair (EVAR) products that consist of stent graft and catheter delivery system under the Powerlink, IntuiTrak, AFX, and VELA brand names. The company also offers endovascular sealing product that is based on the Nellix platform to seal the aneurysm, as well as provides blood flow to the legs through two blood lumens. In addition, it offers aortic extensions and limb extensions, which attach to the main body of its EVAR device, enabling physicians to customize it to fit the patient?s anatomy; and accessories, including guidewires, snares, and catheter introducer sheaths that facilitate the optimal delivery of its EVAR products. Endologix, Inc. sells its products through direct sales force, a network of agents, and independent distributors. The company was formerly known as Radiance Medical Sys

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -4.32% Sales Growth - Q/Q-5.6% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-20.58% ROE-42.54% ROI-24.29%
Current Ratio5.04 Quick Ratio3.76 Long Term Debt/Equity0.64 Debt Ratio0.24
Gross Margin71.79% Operating Margin-22.18% Net Profit Margin-32.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.61 M Cash From Investing Activities4.2 M Cash From Operating Activities-11.73 M Gross Profit26.91 M
Net Profit-11.21 M Operating Profit-9.76 M Total Assets237.76 M Total Current Assets138.41 M
Total Current Liabilities27.45 M Total Debt71.27 M Total Liabilities122.76 M Total Revenue36.67 M
Technical Data
High 52 week9.09 Low 52 week0.93 Last close3.47 Last change-0.57%
RSI39.69 Average true range0.25 Beta0.57 Volume321.74 K
Simple moving average 20 days-6.81% Simple moving average 50 days-27.27% Simple moving average 200 days-44.46%
Performance Data
Performance Week5.15% Performance Month-21.85% Performance Quart-48.82% Performance Half-42.64%
Performance Year110.3% Performance Year-to-date-51.54% Volatility daily4.71% Volatility weekly10.52%
Volatility monthly21.56% Volatility yearly74.69% Relative Volume109.64% Average Volume223.55 K
New High New Low

News

2020-05-12 12:26:22 | Edited Transcript of ELGX earnings conference call or presentation 11-May-20 8:30pm GMT

2020-05-11 17:15:09 | Endologix ELGX Reports Q1 Loss, Tops Revenue Estimates

2020-05-11 16:03:00 | Endologix Announces Completion of Enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System

2020-05-11 16:01:00 | Endologix Reports First Quarter 2020 Financial Results

2020-05-01 16:01:00 | Endologix, Inc. to Announce First Quarter 2020 Financial Results on May 11, 2020

2020-04-14 16:01:00 | Endologix Appoints Tim A. Benner as Chief Commercial Officer

2020-04-06 08:00:00 | Endologix Announces Preliminary Financial Results for First Quarter 2020

2020-03-30 08:00:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2020-03-17 18:30:00 | Endologix Adds Jane E. Kiernan to its Board of Directors

2020-03-16 09:00:00 | Endologix Receives FDA Approval for Alto Abdominal Stent Graft System

2020-03-06 08:00:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2020-02-27 08:39:01 | Is the Options Market Predicting a Spike in Endologix ELGX Stock?

2020-02-24 08:55:00 | Endologix Announces Debt Restructuring Addressing 2020 Maturities

2020-02-22 08:45:01 | Endologix, Inc. Just Reported, And Analysts Assigned A US$3.80 Price Target

2020-02-20 07:06:25 | The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

2020-02-20 01:17:44 | Edited Transcript of ELGX earnings conference call or presentation 19-Feb-20 9:30pm GMT

2020-02-19 17:15:10 | Endologix ELGX Reports Q4 Loss, Misses Revenue Estimates

2020-02-19 16:01:00 | Endologix Reports Fourth Quarter and Fiscal Year 2019 Financial Results

2020-02-19 07:21:54 | The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

2020-02-18 08:00:00 | Endologix, Inc. to Present at the SVB Leerink Global Healthcare Conference

2020-02-12 12:31:05 | Will Endologix ELGX Report Negative Earnings Next Week? What You Should Know

2020-02-07 07:32:45 | The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

2020-02-06 08:30:00 | Endologix Announces Preliminary Financial Results and Conference Call for Fourth Quarter and Full-Year 2019

2020-02-03 08:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2020-01-10 08:19:46 | Those Who Purchased Endologix NASDAQ:ELGX Shares Five Years Ago Have A 99% Loss To Show For It

2020-01-02 16:01:00 | Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference

2019-12-20 18:20:05 | Hedge Funds Are Dumping Endologix, Inc. ELGX

2019-12-10 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-11-11 16:01:00 | Endologix, Inc. to Present at the Stifel Healthcare Conference

2019-11-07 08:57:42 | Edited Transcript of ELGX earnings conference call or presentation 6-Nov-19 9:30pm GMT

2019-11-06 18:15:11 | Endologix ELGX Reports Q3 Loss, Tops Revenue Estimates

2019-11-06 16:01:00 | Endologix Reports Third Quarter 2019 Financial Results

2019-10-30 10:34:02 | Endologix ELGX Expected to Beat Earnings Estimates: Should You Buy?

2019-10-29 07:01:00 | Endologix, Inc. Comments on Recent FDA Update on Type III Endoleaks with AFX® Endovascular AAA System

2019-10-24 16:01:00 | Endologix, Inc. to Announce Third Quarter 2019 Financial Results on November 6, 2019

2019-10-12 09:58:14 | Should You Take Comfort From Insider Transactions At Endologix, Inc. NASDAQ:ELGX?

2019-09-16 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-08-26 07:42:00 | 4 Defensible Healthcare Stocks Gaining While the Market Falls

2019-08-13 13:35:20 | Health Check: How Prudently Does Endologix NASDAQ:ELGX Use Debt?

2019-08-13 00:28:49 | Edited Transcript of ELGX earnings conference call or presentation 8-Aug-19 8:30pm GMT

2019-08-08 17:15:09 | Endologix ELGX Reports Q2 Loss, Tops Revenue Estimates

2019-08-08 16:05:00 | Endologix Announces Exclusive Distributor Agreement with Boston Scientific for the Chinese Market

2019-08-08 16:03:00 | Endologix Receives IDE Approval for the Nellix Chimney EndoVascular Aneurysm Sealing Protocol

2019-08-08 16:01:00 | Endologix Reports Second Quarter 2019 Financial Results

2019-08-01 10:33:02 | Will Endologix ELGX Report Negative Earnings Next Week? What You Should Know

2019-07-15 16:01:00 | Endologix, Inc. to Announce Second Quarter 2019 Financial Results on August 8, 2019

2019-07-11 16:01:00 | Endologix Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2019-06-20 08:34:12 | Endologix, Inc. ELGX Shares March Higher, Can It Continue?

2019-06-20 06:29:20 | Investors Who Bought Endologix NASDAQ:ELGX Shares Five Years Ago Are Now Down 95%

2019-06-17 16:01:00 | Endologix, Inc. to Present at the BMO Prescriptions for Success Healthcare Conference